Cardiopulmonary anomalies in incontinentia pigmenti patients

Int J Dermatol. 2018 Jan;57(1):40-45. doi: 10.1111/ijd.13835. Epub 2017 Dec 2.

Abstract

Background: Incontinentia pigmenti (IP) is a rare inherited genodermatosis that usually involves the skin, and also teeth, oral cavity, central nervous system, eyes, blood with eosinophilia, and rarely skeletal system, breast, heart, and lungs. Skin lesions usually appear early, at birth or within the first 2 weeks of life, with four different phases tending to follow Blaschko lines that may overlap.

Case report: We report a rare case of a neonate with transient reversible pulmonary hypertension that presented at day 9 of life. She manifested increasing dyspnea and deterioration of respiratory dynamics with a serious pulmonary hypertension without a primary pulmonary disease. Hence, oxygen therapy at high flows and nitric oxide have been administered with an initial response, but, subsequently, because of the worsening of the respiratory activity, she underwent sildenafil and bosentan treatment with respiratory dynamics improvement and progressive decrease of the pulmonary pressures.

Conclusion: In literature only a few cases of cardiopulmonary anomalies in IP have been described with different outcomes, and these rare complications are probably underestimated by physicians. We could suppose that microangiopathic damages may have a critical role in endothelial alterations, and these processes are probably shared by multiple organs involved in IP and rarely by lungs and heart.

Publication types

  • Case Reports

MeSH terms

  • Antihypertensive Agents / therapeutic use
  • Bosentan
  • Female
  • Humans
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / etiology*
  • Incontinentia Pigmenti / complications*
  • Infant, Newborn
  • Oxygen Inhalation Therapy
  • Sildenafil Citrate / therapeutic use
  • Sulfonamides / therapeutic use
  • Vasodilator Agents / therapeutic use

Substances

  • Antihypertensive Agents
  • Sulfonamides
  • Vasodilator Agents
  • Sildenafil Citrate
  • Bosentan